@article{71ac6bc278d045819886b8fe8e69814f,
title = "Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer",
author = "{ANZUP Consumer Advisory Panel} and Pezaro, {C. J.} and A. Omlin and K. Mastris and G. Attard and Beer, {T. M.} and Chi, {K. N.} and S. Chowdhury and Davis, {I. D.} and Drake, {C. G.} and {de Bono}, {J. S.} and E. Efstathiou and G. Gravis and Higano, {C. S.} and Maha Hussain and N. James and Logothetis, {C. J.} and Morgans, {Alicia Katherine} and C. Parker and Ryan, {C. J.} and F. Saad and O. Sartor and Small, {E. J.} and Sternberg, {C. N.} and Sweeney, {C. J.} and I. Tannock and B. Tombal and S. Gillessen",
note = "Funding Information: CP: advisory boards (compensated): Novartis. Honoraria: Janssen, Pfizer, Sanofi, Novartis, Astellas. Travel support: Pfizer, Sanofi, Amgen. AO: advisory boards (compensated, institutional): Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support: Bayer, Astellas, Janssen, Sanofi. Research support (institutional): Janssen, Teva. FS: advisory boards, honoraria and research: Amgen, Astellas. Bayer, Janssen, Sanofi, Takeda. SG: advisory boards: AAA, Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Janssen Diagnostics, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis. Advisory Boards (uncompensated): ProteoMediX, ESSA Pharmaceuticals Corp. Speakers Bureau (without personal honorarium): Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).",
year = "2017",
month = aug,
day = "1",
doi = "10.1093/annonc/mdx312",
language = "English (US)",
volume = "28",
pages = "1692--1694",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",
}
